Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Switching from TAF to TDF may help people lose weight, but this must be balanced against the risk of kidney problems and bone loss.
The updated guidance says antiretroviral therapy should be started as soon as possible after diagnosis and outlines the latest options.
Although 71% of survey respondents were aware of PrEP, just 19% had ever used HIV prevention pills.
Research on links between tenofovir, SARS-CoV-2 infection and COVID severity have yielded mixed results, but new study suggests it helps.
Once-daily pill suppressed HBV viral load in nearly two thirds of people with HIV/HBV coinfection.
The PrEP 2-1-1 regimen offers an option to take HIV prevention pills before and after sex instead of every day.
Under provisions of the Affordable Care Act, insurers must cover costs related to PrEP.
New HIV treatment guidelines boost TAF and dolutegravir but warn about Trogarzo and advise against Cabenuva for pregnant people.
Switching from TDF to TAF was associated with a less favorable blood fat profile.
People who switched to such a regimen gained up to 10 pounds in nine months.
Previous studies of the association between tenofovir and the coronavirus have yielded mixed results.
Previous studies of the association between tenofovir and COVID-19 outcomes in people with HIV have yielded mixed results.
However, all integrase inhibitors were associated with similar weight gain.
People living with both viruses remain at risk for hepatocellular carcinoma despite antiviral therapy.
A recent study sheds light on weight gain after switching to new form of tenofovir.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.